Menotropin HMG 75iu Injection (Generic)

Product Overview

Menotropin HMG 75iu Injection (Generic) is a prescription‑only medication that belongs to the class of gonadotropin preparations used primarily in assisted reproductive medicine and endocrinology. It is manufactured by Zydus Lifesciences, a globally recognized pharmaceutical company with a strong track record in hormone‑based therapies. The product is supplied as a sterile lyophilized powder in a single‑use glass vial, with each vial containing 75 international units (IU) of human menopausal gonadotropin (HMG). The packaging offers flexibility through three available pack sizes — 3, 6, or 12 injections — allowing clinicians to select the most appropriate supply for treatment cycles. The indicated therapeutic uses include the induction of ovulation in women with anovulatory or oligo‑ovulatory cycles, the stimulation of endogenous testosterone production in men diagnosed with hypogonadotropic hypogonadism, and adjunctive support for male infertility associated with low gonadotropin levels. Because the medication is derived from the urine of post‑menopausal women, it provides a natural mixture of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) that mimics the physiological actions of these key reproductive hormones.

What is Menotropin HMG 75iu Injection (Generic)

Menotropin HMG refers specifically to a standardized preparation of human menopausal gonadotropin that has been purified and calibrated to contain precisely 75 IU of active hormone per vial. The preparation originates from the collection of urine from post‑menopausal women, a source that is rich in both follicle‑stimulating hormone and luteinizing hormone. After a series of filtration, concentration, and sterilization steps, the final product is freeze‑dried to preserve potency and ease of storage. In its reconstituted form, the solution is administered subcutaneously or intramuscularly, where it engages the gonadotropic receptors on ovarian granulosa cells and Leydig cells in the testes. This binding triggers intracellular signaling cascades that promote follicular maturation in the ovary and stimulate testosterone synthesis in the testes. The dual‑hormone composition distinguishes Menotropin HMG from single‑hormone agents, as it can simultaneously support multiple stages of reproductive physiology, making it especially valuable in protocols that require synchronized ovarian recruitment or in male patients who need to restore physiological androgen levels.

Uses and Benefits

Clinically, Menotropin HMG 75iu Injection is employed in a variety of evidence‑based treatment pathways. In reproductive endocrinology, it is a cornerstone agent for controlled ovarian hyperstimulation (COH) in in‑vitro fertilization (IVF) cycles, where it is used to generate multiple mature oocytes for retrieval. The dosage is titrated according to ovarian reserve markers such as anti‑Müllerian hormone (AMH) and antral follicle count, allowing physicians to optimize the number of follicles while minimizing the risk of ovarian hyperstimulation syndrome. For male patients, the medication is prescribed off‑label to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism, a condition characterized by low gonadotropin secretion that results in insufficient testosterone and impaired sperm production. By restoring endogenous LH and FSH activity, Menotropin HMG can raise serum testosterone and improve sperm count and motility. Additionally, the drug is sometimes utilized in research settings to explore new protocols for fertility preservation, such as in prepubertal oncology patients who require rapid gonadal stimulation before chemotherapy. Across all indications, the therapeutic benefit lies in its ability to provide a physiologic blend of gonadotropins that closely mimics natural hormone fluctuations, thereby enhancing the likelihood of successful reproductive outcomes.

How It Works

The pharmacological action of Menotropin HMG is rooted in its ability to bind to and activate the follicle‑stimulating hormone (FSH) receptor on ovarian granulosa cells and the luteinizing hormone (LH) receptor on thecal cells, as well as the LH receptor on Leydig cells in the testes. Upon receptor activation, intracellular second messenger systems — including cyclic AMP and protein kinase A pathways — are triggered, leading to the up‑regulation of key genes involved in steroidogenesis and follicular development. In the ovary, this results in the recruitment of a cohort of primordial follicles and their progressive growth to the pre‑ovulatory stage, a process that is essential for successful ovulation induction or oocyte retrieval in assisted reproduction. In the male reproductive tract, the LH component stimulates Leydig cells to synthesize and secrete testosterone, while the FSH component acts on Sertoli cells to support spermatogenic cells, thereby enhancing overall sperm production. The concurrent presence of both hormones in a single formulation allows for a more physiologic pulse pattern that mirrors the natural menstrual cycle, which can improve the synchronization of follicular maturation and increase the predictive accuracy of ultrasound‑based monitoring. For a deeper scientific explanation, reputable sources such as the National Center for Biotechnology Information provide extensive reviews of gonadotropin receptor signaling and its clinical implications.

Dosage Guidelines

Dosage of Menotropin HMG 75iu Injection must be individualized by a qualified reproductive endocrinologist or endocrinology specialist, as it depends on patient‑specific factors such as age, baseline hormonal levels, ovarian reserve, and treatment goals. In standard controlled ovarian stimulation protocols, clinicians typically initiate therapy with a single 75 IU subcutaneous injection daily for a period ranging from 2 to 14 days, adjusting the dose upward in increments of 25 to 75 IU based on serial ultrasound assessments of follicular size and estrogen serum concentrations. If the clinical response is suboptimal, the dose may be escalated, whereas an excessive response prompting a high risk of ovarian hyperstimulation syndrome may necessitate dose reduction or cycle cancellation. For male hypogonadism, the usual regimen involves administering 75 IU intramuscularly three times per week for a minimum of 12 weeks, with periodic measurement of serum testosterone to evaluate therapeutic adequacy. Throughout any treatment course, patients are advised to adhere strictly to the prescribed schedule, attend scheduled monitoring appointments, and report any adverse symptoms promptly. Concurrent use of other gonadotropins or ovulation‑inducing agents should only occur under direct medical supervision to avoid unintended hormonal excess.

Side Effects

Like all hormone‑based medications, Menotropin HMG can be associated with a spectrum of side effects, ranging from mild and self‑limiting to more serious conditions that require medical intervention. The most frequently reported adverse events include mild abdominal discomfort, bloating, headache, breast tenderness, and irritation at the injection site, which typically resolve without specific treatment. More clinically significant reactions may involve ovarian hyperstimulation syndrome (OHSS), a potentially serious condition characterized by rapid follicular growth, ascites, and altered serum electrolyte levels; patients experiencing severe abdominal pain, shortness of breath, or markedly elevated estrogen levels should seek immediate medical attention. Rare but noteworthy complications include allergic dermatitis, urinary tract infections, and, in exceptional cases, thromboembolic events, particularly in individuals with underlying risk factors. Long‑term safety data are limited, hence clinicians are encouraged to monitor patients regularly and to document any unexpected outcomes in the product’s pharmacovigilance database. For comprehensive safety information, healthcare providers can consult the FDA’s drug label or the Drugs.com database, which summarize reported adverse reactions and their management strategies.

Warnings and Precautions

Menotropin HMG is contraindicated in patients with a known hypersensitivity to any component of the formulation, as well as in individuals with active pelvic or reproductive tract infections, uncontrolled thyroid disease, or hormone‑sensitive malignancies such as certain forms of ovarian or breast cancer. The medication should be used with caution in patients who have a history of thromboembolic disorders, severe cardiovascular disease, or untreated adrenal insufficiency, as hormonal fluctuations can exacerbate these conditions. Prior to initiation, a thorough clinical evaluation — including baseline hormone panels, pelvic ultrasound, and, when indicated, semen analysis — is essential to determine suitability and to establish a monitoring plan. Concomitant administration of other gonadotropins, clomiphene citrate, or aromatase inhibitors may increase the risk of multiple pregnancies or ovarian hyperstimulation, therefore such combinations must be supervised by a specialist. Pregnant or breastfeeding women should not receive Menotropin HMG, as its pharmacologic activity could affect fetal development or infant health. Finally, healthcare providers are required to counsel patients about the possibility of multiple gestations and to discuss reproductive options in the context of informed consent.

Frequently Asked Questions

1. What condition does Menotropin HMG 75iu Injection treat?
It is indicated for female infertility due to anovulation or oligo‑ovulation, male hypogonadism, and male infertility associated with low gonadotropin levels.

2. How should the medication be stored?
Store the vial in a refrigerator at 2°C–8°C, protected from light. Do not freeze. Once opened, the injection should be used promptly and discarded according to local regulations.

3. Can Menotropin HMG be used in combination with other fertility drugs?
Yes, it is often combined with gonadotropin‑releasing hormone (GnRH) antagonists or agonists and assisted reproductive techniques such as IVF, but the exact protocol must be supervised by a reproductive endocrinologist.

4. Is there a risk of multiple pregnancies?
Because the drug can stimulate the development of multiple follicles, the likelihood of twins or higher‑order multiples is increased. Close ultrasound monitoring helps mitigate this risk.

5. Where can I find more detailed prescribing information?
Full prescribing details are available on the FDA Drugs@FDA database and in the product’s package insert provided by Zydus Lifesciences.

Related Products

• Iladac 10 Mg (Ilaprazole)
• Ilaprazole 10 Mg (Generic)
• Dexona 4mg Injection (Dexamethasone)
• Dexamethasone 4mg Injection (Generic)
• Oxemia 100 Mg
• Oxemia 50mg
• Obnyx 40 mg Capsule (Enzalutamide)
• Doxolin 200mg (Doxofylline)
• Doxofylline 200mg (Generic)
• Bistide 3 mg (Plecanatide)
• Imeglyn 1000 Mg (Imeglimin)
• Imeglyn 500 Mg (Imeglimin)